



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Alflutinib (mesylate)

Item No. 31473

CAS Registry No.: 2130958-55-1

Formal Name: N-[2-[[2-(dimethylamino)ethyl]methylamino]-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]-2-propenamide, monomethanesulfonate

Synonym: AST2818

MF: $C_{28}H_{31}F_3N_8O_2 \cdot CH_3SO_3H$

FW: 664.7


Purity: $\geq 98\%$

UV/Vis.: λ_{max} : 267, 332 nm

Supplied as: A crystalline solid

Storage: $-20^\circ C$

Stability: ≥ 2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Alflutinib (mesylate) is supplied as a crystalline solid. A stock solution may be made by dissolving the alflutinib (mesylate) in the solvent of choice, which should be purged with an inert gas. Alflutinib (mesylate) is soluble in the organic solvent chloroform at a concentration of approximately 10 mg/ml. Alflutinib (mesylate) is also slightly soluble in DMSO and dimethyl formamide.

Description

Alflutinib is an inhibitor of mutant EGFRs.¹ It is selective for EGFR^{L858R}, EGFR^{G719X}, EGFR^{L858R}, EGFR^{L861A}, and EGFR^{T790M} mutant EGFRs over wild-type EGFR. Alflutinib (10 and 30 mg/kg) reduces tumor growth in an EGFR^{L858R} and EGFR^{T790M}-expressing LU1868 non-small cell lung cancer (NSCLC) patient-derived xenograft (PDX) mouse model.

Reference

1. Shi, Y., Zhang, S., Hu, X., *et al.* Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation. *J. Thorac. Oncol.* **15**(6), 1015-1026 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/14/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM